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Introduction {#sec005}
============

Since the end of 2019, the World Health Organization (WHO) recommends to use an injectable-free shorter treatment regimen for the treatment of rifampicin-resistant tuberculosis (RR-TB) \[[@pone.0238016.ref001]\]. However, this recommendation has a "very low certainty in the estimate of the effect" from a 2018 meta-analysis, and is conditional, "recognizing that different choices will be appropriate for individual patients" \[[@pone.0238016.ref002]\]. In fact, results of ongoing comparative trials, such as STREAM II where bedaquiline is substituted for kanamycin in one of the arms, have not yet been published. The recommendation was informed by unpublished results from a South African cohort study and the 2018 metanalysis comparing the effect of drugs but not of regimens, ignoring outcomes such as recurrence due to acquisition of resistance to the regimen's core drug \[[@pone.0238016.ref003]\].

Since decades, second-line injectables, such as kanamycin, amikacin, and capreomycin have been used for the treatment of RR-TB. A 2012 meta-analysis showed that treatment success was most likely when second-line injectables were used during the first 8 months of treatment in long treatment regimens \[[@pone.0238016.ref004]\]. A subsequent meta-analysis confirmed that initial susceptibility to fluoroquinolone and the second-line injectables were the strongest predictors of treatment success \[[@pone.0238016.ref005]\].

Between 1997--2007 the shorter treatment regimen (STR) was developed in Bangladesh. Stepwise, six different short regimens were evaluated \[[@pone.0238016.ref006]\]. Modifications that may seem minor had important consequences on the bacteriological effectiveness of the regimens, and showed that constructing TB treatment regimens is more complex than combining "at least four likely active drugs" \[[@pone.0238016.ref006], [@pone.0238016.ref007]\]. The most effective STR used a 4-month intensive phase. To avoid relapse due to a high bacillary load this intensive phase was extended by a maximum of two months in case smear-conversion was not achieved at four months. During the intensive phase kanamycin, prothionamide, and high-dose isoniazid were added to a background regimen that included high-dose gatifloxacin as the later generation fluoroquinolone, ethambutol, clofazimine and pyrazinamide \[[@pone.0238016.ref006]\]. The STR also showed to be highly effective in Niger and Cameroon, which also used gatifloxacin \[[@pone.0238016.ref008], [@pone.0238016.ref009]\]. Use of the STR was recommended in WHO's 2016 guidelines \[[@pone.0238016.ref007]\], and the first STREAM trial showed that its moxifloxacin-based variant was non-inferior to 20-month long RR-TB regimens. The twenty-month regimens included an intensive phase containing a second-line injectable for a minimum of 8 months \[[@pone.0238016.ref010]\].

Although the duration of second-line injectable administration was shortened from at least eight months in long regimens to at least four months in the STR, the incidence of severe adverse events, in particular hearing loss, warranted studies on regimens that further reduced use of second-line injectables. For streptomycin, clearly suboptimal effectiveness had been documented when it was used for only the first month in the 8-month first-line regimen, with rifampicin and pyrazinamide for the first two months and isoniazid throughout (complemented by thioacetazone after the first two months). Whether its use beyond the second month improved the results was not assessed, possibly because there were zero recurrences after the regimen with streptomycin for two months, versus 7% relapse, half with acquired isoniazid resistance, if given during the first month only \[[@pone.0238016.ref011]\]. To our best knowledge trials on the optimal duration of second-line injectables for RR-TB have not been conducted. In this study we therefore document the assessed effect on bacteriological outcomes of shortening the duration of kanamycin administration from four to two months, without changing the duration for the other drugs used during the intensive phase. Bacteriological outcomes included recurrence (either failure or relapse) and resistance acquisition to gatifloxacin.

Methods {#sec006}
=======

Study population {#sec007}
----------------

This retrospective study uses data collected during the evaluation of the STR in Bangladesh. Patients diagnosed with bacteriologically confirmed RR-TB and who started treatment with a gatifloxacin-based STR between December 2005 and October 2015 were included. The modified regimen, with 2 months of kanamycin during the 4(+)-month intensive phase was used in the second half of 2011 only. All other procedures, including monitoring, were the same. The composition of regimens is shown in [Table 1](#pone.0238016.t001){ref-type="table"}. To assess the bacteriological effect of the STR, patients lost to follow-up and those who died were excluded.

10.1371/journal.pone.0238016.t001

###### Composition of gatifloxacin-based shorter treatment regimens used in Bangladesh.

![](pone.0238016.t001){#pone.0238016.t001g}

                 Enrolment period   Intensive phase [\#](#t001fn003){ref-type="table-fn"}   Continuation phase
  -------------- ------------------ ------------------------------------------------------- --------------------
  Standard STR   2005--2015         4(+) KCG^h^EH^h^ZP                                      5 G^h^EZC
  Modified STR   2011 sem. II       2KCG^h^EH^h^ZP / 2(+) CG^h^EH^h^ZP                      5 G^h^EZC

C: clofazimine; E: ethambutol; G^h^: high-dose gatifloxacin; H^h^: high-dose isoniazid; K: kanamycin; P: prothionamide; Z: pyrazinamide

STR: shorter treatment regimen; sem. II: second semester

\# The standard duration of the intensive phase was 4 months, but was extended until negative on sputum smear microscopy.^12^

Data collection and analysis {#sec008}
----------------------------

Patient follow-up, data collection, and drug susceptibility testing methods were described in detail in a previously published paper \[[@pone.0238016.ref012]\]. Recurrence included treatment failure and relapse, diagnosed using active follow-up including 6-monthly cultures for two years after cure. Treatment outcomes are also shown in a previously published paper \[[@pone.0238016.ref013]\]. In short, treatment failure was defined as having a positive culture between the end of the 5th treatment month and the end of treatment. Relapse was defined as having at least one positive culture after the end of successful treatment. Results showing resistance, detected by any genotypic or phenotypic method, overrode results from another sputum showing susceptibility. Initial fluoroquinolone resistance was categorized as 'high-level' if the strain grew on agar or Löwenstein--Jensen medium at ≥8 mg/L OFX or if the minimum inhibitory concentration (MIC) for GFX was ≥2 mg/L. Resistance was defined as acquired when resistance was detected on the recurrence isolate but not present at baseline, and with DNA fingerprinting showing the same strain.

Bivariable logistic regression was used to assess the correlation between regimen (regimen with 4(+) months kanamycin versus 2 months kanamycin in the intensive phase), initial resistance to fluoroquinolone, and initial resistance to kanamycin and having a bacteriologically adverse outcome. Bacteriologically adverse outcomes included recurrence and acquired resistance to fluoroquinolone. The Kruskal--Wallis test was used to compare the median duration of the intensive phase between regimens.

Ethics {#sec009}
------

The evaluation of the STR is fully covered by a study protocol approved by the National Research Ethics Committee of Bangladesh Medical Research Council and the Institutional Review Board of the Institute of Tropical Medicine Antwerp. All patients completed and signed an informed consent form in the local language before starting treatment.

Results {#sec010}
=======

[Fig 1](#pone.0238016.g001){ref-type="fig"} shows enrolment in the study of patients treated with the standard gatifloxacin-based STR, with 4(+) months of kanamycin, or the modified STR, with 2 months of kanamycin. Of 928 patients treated with a gatifloxacin-based regimen, 790 were included in the analyses after exclusion of those who died or were lost to follow-up.

![Study enrolment and treatment outcomes among 928 patients treated with a gatifloxacin-based regimen in Bangladesh.\
LTFU: lost to follow-up; GFX: gatifloxacin; STR: shorter treatment regimen.](pone.0238016.g001){#pone.0238016.g001}

The distribution of sex and age was not significantly different among patients treated with the modified STR (2 months of kanamycin) compared to those treated with the standard STR (4(+) months of kanamycin) ([Table 2](#pone.0238016.t002){ref-type="table"}).

10.1371/journal.pone.0238016.t002

###### Age and gender stratified by regimen, either 2 months or 4(+) months of kanamycin in 790 RR-TB patients treated with a gatifloxacin-based shorter treatment regimen in Bangladesh.

![](pone.0238016.t002){#pone.0238016.t002g}

                   Total   Kanamycin during the intensive phase                            
  ---------------- ------- -------------------------------------- ----- ------ ---- ------ -----
  Total            790                                            738          52           
  **Sex**                                                                                  0.1
  Female           243     30.8                                   222   30.1   21   40.4   
  Male             547     69.2                                   516   69.9   31   59.6    
  **Age group**                                                                            0.1
  \< = 18 years    76      9.6                                    68    9.2    8    15.4   
  \>18--35 years   409     51.8                                   378   51.2   31   59.6   
  \>35--50 years   207     26.2                                   199   27     8    15.4   
  \>50 years       98      12.4                                   93    12.6   5    9.6     

Of 738 patients on the standard STR (4(+) months of kanamycin) and 52 on the modified STR (2 months of kanamycin), 717 (97.2%) and 47 (90.4%) were treated successfully, respectively. The median duration of the intensive phase was similar for both cohorts: 120 days (IQR 119--127) for those treated with the standard STR and 120 days (IQR 119--121) for those treated with the modified STR (p = 0.1).

Of 790 patients on a gatifloxacin-based STR, 52 were treated with a modified regimen, with two months of kanamycin ([Table 3](#pone.0238016.t003){ref-type="table"}). Recurrence was detected in 21 of 738 (2.8%) patients treated with 4(+) months of kanamycin and five of 52 (9.6%) treated with two months of kanamycin. Using two months instead of 4(+) months of kanamycin was significantly associated with recurrence (OR 3.7; 95%CI: 1.5--10.3), as were low-level (OR 12.8; 95%CI: 3.1--53.4) and high-level (OR 107.2; 95%CI: 35.9--320.1) initial resistance to fluoroquinolone, and initial resistance to kanamycin (OR 31.7; 95%CI: 6.8--147.4).

10.1371/journal.pone.0238016.t003

###### Effect of using 2 months of kanamycin instead of 4(+) months on recurrence in 790 RR-TB patients treated with a gatifloxacin-based shorter treatment regimen in Bangladesh.

![](pone.0238016.t003){#pone.0238016.t003g}

                                             Total   Recurrence   [\$](#t003fn004){ref-type="table-fn"}    OR [\#](#t003fn005){ref-type="table-fn"}         \[95%CI\]
  ------------------------------------------ ------- ------------ ---------------------------------------- ------------------------------------------------ ----------------
  **Kanamycin during the intensive phase**                                                                                                                   
  4(+) months                                738     21           2.8                                      1                                                
  2 months                                   52      5            9.6                                      3.7[\*\*](#t003fn002){ref-type="table-fn"}       \[1.5,10.3\]
  **Initial fluoroquinolone resistance**                                                                                                                    
  Susceptible                                684     4            0.6                                      1                                                
  Resistant low-level                        44      3            6.8                                      12.8[\*\*\*](#t003fn003){ref-type="table-fn"}    \[3.1,53.4\]
  Resistant high-level                       46      19           41.3                                     107.2[\*\*\*](#t003fn003){ref-type="table-fn"}   \[35.9,320.1\]
  Missing                                    16      0            0                                        NA                                                
  **Initial kanamycin resistance**                                                                                                                          
  Susceptible                                767     23           3                                        1                                                
  Resistant                                  6       3            50                                       31.7[\*\*\*](#t003fn003){ref-type="table-fn"}    \[6.8,147.4\]
  Missing                                    17      0            0                                        NA                                                

\* p\<0.05

\*\* p\< 0.01

\*\*\* p\<0.001

\$ Recurrence: either treatment failure or relapse

\# Firth logistic regression was used as events were rare. For the same reason no multivariable model was developed.

In 189 of 738 patients on the standard STR, the intensive phase (with additional high-dose isoniazid, ethionamide and kanamycin) was extended. Of 189, 10 (5.3%) experienced recurrence (8 treatment failure, 2 relapse, but without acquisition of resistance to fluoroquinolone). In two of 52 patients on the modified regimen, the intensive phase (with additional high-dose isoniazid and ethionamide, but not with kanamycin) was extended beyond 4 months, but without success (both experienced treatment failure with acquisition of resistance to fluoroquinolone, and later died of active TB because an adequate regimen could not be constituted or was refused by the patient).

None of 52 patients treated with the STR containing two months of kanamycin had clinical signs of hearing loss (audiometry was not in place). Data on clinical monitoring was available for 515 patients treated with the standard STR and showed hearing loss in 26 (5.0%) patients.

Of 683 patient with initially fluoroquinolone-susceptible and kanamycin-susceptible TB, 44 were treated with a modified regimen, with two months of kanamycin ([Table 4](#pone.0238016.t004){ref-type="table"}). Acquired resistance to fluoroquinolone was detected in none of 639 patients treated with 4(+) months of kanamycin and two (4.5%) of 44 treated with two months of kanamycin. Using two months instead of 4(+) months of kanamycin was associated with recurrence (OR 15.0; 95%CI: 2.5--89.0) and fluoroquinolone acquired drug resistance (OR 75.2; 95%CI: 3.6--1592.1).

10.1371/journal.pone.0238016.t004

###### Effect of using 2 months of kanamycin instead of 4(+) months on recurrence and fluoroquinolone acquired drug resistance in 683 patients with initially fluoroquinolone-susceptible/kanamycin-susceptible RR-TB, treated with a gatifloxacin-based shorter treatment regimen in Bangladesh.

![](pone.0238016.t004){#pone.0238016.t004g}

                                                   Recurrence [\$](#t004fn002){ref-type="table-fn"}                                                 Fluoroquinolone acquired drug resistance [£](#t004fn003){ref-type="table-fn"}                                                           
  -------------------------------------- ----- --- -------------------------------------------------- --------------------------------------------- ------------------------------------------------------------------------------- --- ----- --------------------------------------------- ----------------
  Kanamycin during the intensive phase                                                                                                                                                                                                                                                       
  4(+) months                            639   2   0.3                                                1                                                                                                                             0   0     1                                             
  2 months                               44    2   4.5                                                15.0[\*\*](#t004fn001){ref-type="table-fn"}   \[2.5,89.0\]                                                                    2   4.5   75.2[\*\*](#t004fn001){ref-type="table-fn"}   \[3.6,1592.1\]

\*\* p\< 0.01

\$ Recurrence: either treatment failure or relapse

£ Fluoroquinolone acquired drug resistance: fluoroquinolone resistance in recurrence sample for patients with initially fluoroquinolone-susceptible tuberculosis in the same strain as shown by DNA fingerprinting

\# Firth logistic regression was used as events were rare. For the same reason no multivariable model was developed.

Discussion {#sec011}
==========

In this study we compared two STR regimens: a standard STR including kanamycin throughout the 4(+) month intensive phase, and a modified STR that included 2 months of kanamycin during the 4(+) month intensive phase. The only difference between both regimens was the duration of kanamycin administration. The aim to avoid ototoxicity by halving the amount of injectable may have been reached. Clinical monitoring did not reveal a single case among the 52 patients of the 2 month kanamycin cohort, compared to the 5% in the cohort using kanamycin throughout the intensive phase, also monitored clinically, or the 7% of serious hearing loss reported for the African STR study that used audiometry \[[@pone.0238016.ref014]\]. However, the frequency of bacteriologically adverse outcomes, such as recurrence and acquired resistance to the core drug, were significantly more frequent when kanamycin administration was limited to two months. These results are coherent with those from a trial in patients with rifampicin-susceptible TB, which also showed a higher frequency of recurrence and acquired resistance to other drugs in the regimen when the duration of the injectable (streptomycin in this trial) was reduced from 2 to one month \[[@pone.0238016.ref011]\]. Shortening the duration of injectables in RR-TB treatment regimens was not yet studied.

The gatifloxacin-based STR is the first treatment regimen that consistently achieved high RR-TB treatment success as well as very low recurrence rates without creating any additional resistance to this core drug in a wide range of countries, and does so for more than a decade \[[@pone.0238016.ref015]\]. In contrast with the WHO recommended approach of combining "at least 4 likely active drugs" \[[@pone.0238016.ref002]\], the effectiveness of the STR stems from combining drugs with complementary activity \[[@pone.0238016.ref016]\]. Based on data from numerous clinical trials forming the cornerstone of current first-line regimens, the specific activities of different TB drugs accounting for the effectiveness of a regimen were first described by the late Prof. Mitchison \[[@pone.0238016.ref017]\]. Maybe his most important conclusion was that, with susceptible bacilli, the efficacy of a combination of isoniazid, rifampicin and pyrazinamide could be enhanced only very little by the addition of streptomycin, and not at all by ethambutol \[[@pone.0238016.ref018]\]. Streptomycin also prevented acquired resistance when added to isoniazid, rifampicin and pyrazinamide in high risk patients with very high recurrence rates \[[@pone.0238016.ref019]\]. Both streptomycin and ethambutol were classified as companion drugs, indicated for prevention of acquired resistance to the more effective drugs. Streptomycin was rated to be stronger \[[@pone.0238016.ref018]\].

A multi-country study clearly showed that all three second-line injectables protect against acquired resistance to the driving fluoroquinolone core drug \[[@pone.0238016.ref020]\], and also the present study underpins that kanamycin plays this crucial role. In the STR a later generation fluoroquinolone (preferably gatifloxacin) \[[@pone.0238016.ref013]\] is the core drug, contributing most to achieving relapse-free cure through high bactericidal and high sterilizing activity. As only few drugs have this characteristic, core drugs need to be protected, to prevent resistance acquisition and the loss of a highly effective standardized regimen \[[@pone.0238016.ref016]\]. Isoniazid protects rifampicin in first-line treatment rifampicin-throughout regimens \[[@pone.0238016.ref021]\], whereas kanamycin protects the fluoroquinolone in the STR. Indeed, in patients without sputum smear conversion at 4 months, the intensive phase was prolonged with ethionamide, high-dose isoniazid and with kanamycin in addition to the background regimen when the standard STR was used, but without kanamycin in the modified STR (kanamycin was already stopped at month 2). Extending the intensive phase was not successful when kanamycin was not included. Both patients on the modified STR in whom the intensive phase was extended experienced treatment failure with acquisition or resistance to fluoroquinolone. Even though numbers were small for the modified STR cohort, this finding suggests that, given sufficient time, kanamycin succeeds in reducing numbers of mutants resistant to the core drug to a clinically irrelevant level, where other companion drugs with little bactericidal activity fail \[[@pone.0238016.ref016]\].

The 2018 meta-analysis declared that the second-line injectables kanamycin and capreomycin were not effective and that amikacin had a modest beneficial effect on treatment success. However, it did not assess acquired resistance preventing action \[[@pone.0238016.ref003]\]. Indeed, as for streptomycin in the original first-line regimens clinical trials, initial susceptibility to second-line injectables is not expected to significantly improve success. Also in our two-month kanamycin cohort, relapse-free cure was not lower than published for the 4(+) month kanamycin cohort \[[@pone.0238016.ref012]\] due to overall very low rates of adverse outcomes. The lack of second-line injectable early bactericidal activity (EBA) is often taken as an argument for their lack of activity. However, to the best of our knowledge only amikacin EBA values over not more than two days have been published. No difference with untreated controls could be shown, but the authors added that the bacterial fall seen in the controls was unprecedented \[[@pone.0238016.ref022]\]. Of interest, while the same group reported 2-day EBA close to zero for streptomycin standard dose (15 mg/kg), similar to the value reported for amikacin, EBA was significantly higher at double dose \[[@pone.0238016.ref023]\]. Besides EBA estimates being prone to considerable variation, assessment at two days treatment is not appropriate for all TB drugs \[[@pone.0238016.ref024]\]. Highly active TB drugs such as pyrazinamide, clofazimine and bedaquiline show their full EBA after a delay of about two weeks \[[@pone.0238016.ref025]\]. In the case of clofazimine this had led to contradicting findings, depending on the test system used \[[@pone.0238016.ref026]\]. As a result, it was recognized as a valuable TB drug only after its sterilizing power in mice had been demonstrated \[[@pone.0238016.ref027]\], although its activity against TB bacilli had been known for 60 years \[[@pone.0238016.ref028]\]. In mice, streptomycin and amikacin were highly bactericidal in the first months, but particularly streptomycin failed to complete sterilization \[[@pone.0238016.ref029]\]. In vitro the bacillary kill after one week was larger for streptomycin than for isoniazid or rifampicin \[[@pone.0238016.ref030]\]. Sophisticated in-vitro experiments showed a 2-log kill by amikacin in the first two days, and this for dormant as well as actively replicating TB bacilli \[[@pone.0238016.ref031]\].

In summary, these reports testify of an immediate very large and rapid kill of TB bacilli, irrespective of metabolic state, continuing though the early phase of treatment when numbers of still replicating resistant mutants are highest. This is highly consistent with the resistance preventing role assigned to streptomycin and the second-line injectables. Only amikacin was attributed an additional modest contribution to sterilization, which may explain why it was the only second-line injectable recognized as having an effect on treatment success by the 2018 meta-analysis \[[@pone.0238016.ref003]\]. Furthermore, effectiveness of these drugs strongly depends on peak serum concentration, the reason why pharmacologists recommend testing a higher dose, to achieve high serum peaks for optimal effectiveness, with intermittent instead of daily administration so as to reduce the total amount administered and thus toxicity \[[@pone.0238016.ref032]\]. As toxicity is correlated with the cumulative drug exposure to any second-line injectable during different treatment episodes \[[@pone.0238016.ref033]\], toxicity will be reduced further because streptomycin is no longer used in first-line retreatment regimens \[[@pone.0238016.ref034]\]. One could then imagine the return of a valuable drug that was discarded due to excess toxicity, simply by total dose reduction. In the past, pyrazinamide was abandoned because of excessively frequent hepatotoxicity \[[@pone.0238016.ref035]\], but it became one of the cornerstones of short-course chemotherapy, once it was found to be effective at close to half the original dose \[[@pone.0238016.ref036]\].

We believe that the second-line injectables have been discarded prematurely \[[@pone.0238016.ref001]\], based on rates of ototoxicity when they had to be used for at least eight months in patients who often had prior exposure to streptomycin \[[@pone.0238016.ref037]\], and with remarkable disregard of their essential contribution to a regimen in the context of the current new-TB-drug-euphoria. We strongly recommend that studies assessing the effect of injectable-free STR also assess the effect of this modification on bacteriological outcomes such as recurrence and resistance acquisition. Meanwhile, in patients with a contra-indication for the use of second-line injectables, such as those with baseline hearing impairment, those who develop adverse events, or those with initial resistance to second-line injectables, the second-line injectable can be replace by linezolid. Experience from Niger shows that this approach can prevent severe ototoxicity and that linezolid related adverse events were manageable. Similar cure rates were achieved in patients treated with the standard STR and in those treated with a modified STR, using linezolid instead of kanamycin \[[@pone.0238016.ref038]\].

Our study has several strengths and limitations. We were able to assess the effect of two months versus 4(+) months of kanamycin in the intensive phase on bacteriological outcomes as the regimens included in this study were the same, except for the duration of kanamycin administration. Using a continuously updated database all patients registered as having started treatment were included in the analysis, including that of relapse after cure. Our study also has some limitations. Patients were not randomly assigned to regimens. Moreover, the sample of patients treated with the modified regimen was small, because enrolment was stopped as soon as the second case of acquired fluoroquinolone resistance was reported, which had never been encountered with the unmodified gatifloxacin regimen. Both cases ultimately died of active TB because an adequate regimen could not be constituted or was refused by the patient. Excess mortality is too high a price to pay for preventing ototoxicity.

In conclusion, 2 months of kanamycin during the intensive phase of the RR-TB STR was insufficient to prevent recurrence with acquired resistance to high-dose gatifloxacin, the most powerful fluoroquinolone and core drug of the regimen. Our findings confirm the important role of second-line injectable drugs with regards to bacteriological outcomes. Future studies on all-oral regimens should not only assess composite endpoints, combining mortality, loss to follow-up, and recurrence, but also the effect of regimen composition on resistance acquisition. Moreover, these should also report on the composition and effectiveness of salvage regimens for patients who fail an all-oral regimen. Meanwhile, it may be wiser to continue using a second-line injectable, replacing it by linezolid in case hearing impairment is identified.

We thank the study participants and staff of Damien Foundation Bangladesh.
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Please include both an updated Funding Statement and Competing Interests Statement in your cover letter. We will change the online submission form on your behalf.

Please know it is PLOS ONE policy for corresponding authors to declare, on behalf of all authors, all potential competing interests for the purposes of transparency. PLOS defines a competing interest as anything that interferes with, or could reasonably be perceived as interfering with, the full and objective presentation, peer review, editorial decision-making, or publication of research or non-research articles submitted to one of the journals. Competing interests can be financial or non-financial, professional, or personal. Competing interests can arise in relationship to an organization or another person. Please follow this link to our website for more details on competing interests: [http://journals.plos.org/plosone/s/competing-interests](about:blank)

Reviewers\' comments:

Reviewer\'s Responses to Questions

**Comments to the Author**

1\. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer \#1: Yes

\*\*\*\*\*\*\*\*\*\*

2\. Has the statistical analysis been performed appropriately and rigorously?

Reviewer \#1: Yes

\*\*\*\*\*\*\*\*\*\*

3\. Have the authors made all data underlying the findings in their manuscript fully available?

The [PLOS Data policy](http://www.plosone.org/static/policies.action#sharing) requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data---e.g. participant privacy or use of data from a third party---those must be specified.

Reviewer \#1: Yes

\*\*\*\*\*\*\*\*\*\*

4\. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer \#1: Yes

\*\*\*\*\*\*\*\*\*\*

5\. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer \#1: The authors demonstrate in scientifically sound and convincing way the important role played by 2nd line injectables in preventing recurrence with acquired resistance to Gatifloxacine, the core drug in the hitherto most effective shorter treatment regimen (STR) of rifampicin resistant tuberculosis (RR-TB). Subsequently, they plead for the necessity to include in the evaluation of all-oral RR-TB regimens - promoted since 2019 by WHO alternatively to STRs including injectables - an assessment of regimen compositions on resistance acquisition. The study is an important contribution to the ongoing discussion about merit and virtue of the standardized 'Bangladesh' STR and its variants using injectables for programmatic management of RR-TB in L/MICs where treatment options after recurrence are limited and will be so in a foreseeable future.

Minor suggestions

Title

Consider adding "...in RR-TB STR..."

Discussion

L289-90 Also understandable from the context, consider re-wording (...two days is not

appropriate for all TB drugs." -- "Two days of (what)...".

\*\*\*\*\*\*\*\*\*\*

6\. PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).

Reviewer \#1: No

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, <https://pacev2.apexcovantage.com/>. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at <figures@plos.org>. Please note that Supporting Information files do not need this step.

10.1371/journal.pone.0238016.r002

Author response to Decision Letter 0

31 Jul 2020

Dear Editor,

Many thanks for the review of \"Injectables' key role in rifampicin-resistant tuberculosis shorter treatment regimen outcomes\". We have adapted the paper accordingly.

A revised manuscript showing modifications in track changes was uploaded, as well as a clean version and this rebuttal.

We shall of course be available to respond to any additional question you may have.

Kind regards,

Tom Decroo, on behalf of the co-authors

\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

PONE-D-20-18936

Injectables' key role in rifampicin-resistant tuberculosis treatment outcomes

PLOS ONE

Dear Dr. Decroo,

Thank you for submitting your manuscript to PLOS ONE. Your manuscript was evaluated very positively by an independent referee and myself. Referee \#1 raised a couple of minor concerns that should be addressed before we can proceed with formal acceptance. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

Please submit your revised manuscript by Sep 13 2020 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at <plosone@plos.org>. When you\'re ready to submit your revision, log on to <https://www.editorialmanager.com/pone/> and select the \'Submissions Needing Revision\' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

• A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled \'Response to Reviewers\'.

• A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled \'Revised Manuscript with Track Changes\'.

• An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled \'Manuscript\'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: <http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols>

We look forward to receiving your revised manuscript.

Kind regards,

Olivier Neyrolles

Academic Editor

PLOS ONE

Journal requirements:

When submitting your revision, we need you to address these additional requirements.

1\. Please ensure that your manuscript meets PLOS ONE\'s style requirements, including those for file naming. The PLOS ONE style templates can be found at

<https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf> and

<https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf>

2\. Thank you for stating in your ethics statement \"The evaluation of the STR is covered by a study protocol approved by the National Research Ethics Committee of Bangladesh Medical Research Council and the Institutional Review Board of the Institute of Tropical Medicine Antwerp (1233/18).\" Please clarify whether this specific study was fully approved by these ethics committees.

RESPONSE: The approved protocols cover the objectives, data collection procedures, and analysis of the present study. We adapted the statement as follows: "The evaluation of the STR is fully covered by a study protocol approved by the National Research Ethics Committee of Bangladesh Medical Research Council and the Institutional Review Board of the Institute of Tropical Medicine Antwerp (1233/18)."

3\. Please provide a summary table of patient demographics.

RESPONSE: We added a summary table with age and gender, now "table 2" and added a sentence in the results text.

4.We note that you have indicated that data from this study are available upon request. PLOS only allows data to be available upon request if there are legal or ethical restrictions on sharing data publicly. For information on unacceptable data access restrictions, please see <http://journals.plos.org/plosone/s/data-availability#loc-unacceptable-data-access-restrictions>.

In your revised cover letter, please address the following prompts:

a\) If there are ethical or legal restrictions on sharing a de-identified data set, please explain them in detail (e.g., data contain potentially identifying or sensitive patient information) and who has imposed them (e.g., an ethics committee). Please also provide contact information for a data access committee, ethics committee, or other institutional body to which data requests may be sent.

RESPONSE: There are ethical and privacy concerns with sharing the dataset. Given the stigma associated with RR-TB disease and to maximally protect the patient's privacy we prefer to not share the database in an unrestricted manner. Some specific medical data (combination of a rare outcome + age + gender +++ ...) might enable re-identification, even though identifiers such as names and addresses were removed from the programme dataset prior to analysis.

We propose the following statement: "The data supporting the findings of this publication are retained at the Institute of Tropical Medicine, Antwerp and will not be made openly accessible due to ethical and privacy concerns. Data can however be made available after approval of a motivated and written request to the Institute of Tropical Medicine at <ITMresearchdataaccess@itg.be>"

b\) If there are no restrictions, please upload the minimal anonymized data set necessary to replicate your study findings as either Supporting Information files or to a stable, public repository and provide us with the relevant URLs, DOIs, or accession numbers. Please see <http://www.bmj.com/content/340/bmj.c181.long> for guidelines on how to de-identify and prepare clinical data for publication. For a list of acceptable repositories, please see <http://journals.plos.org/plosone/s/data-availability#loc-recommended-repositories>.

We will update your Data Availability statement on your behalf to reflect the information you provide.

5.Thank you for stating the following in the Financial Disclosure section:

\[The authors received no specific funding for this work.\].

RESPONSE: We added this statement under "Funding".

We note that one or more of the authors have an affiliation to the commercial funders of this research study : Independent Consultant

1\. Please provide an amended Funding Statement declaring this commercial affiliation, as well as a statement regarding the Role of Funders in your study. If the funding organization did not play a role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript and only provided financial support in the form of authors\' salaries and/or research materials, please review your statements relating to the author contributions, and ensure you have specifically and accurately indicated the role(s) that these authors had in your study. You can update author roles in the Author Contributions section of the online submission form.

Please also include the following statement within your amended Funding Statement.

"The funder provided support in the form of salaries for authors \[insert relevant initials\], but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The specific roles of these authors are articulated in the 'author contributions' section."

If your commercial affiliation did play a role in your study, please state and explain this role within your updated Funding Statement.

2\. Please also provide an updated Competing Interests Statement declaring this commercial affiliation along with any other relevant declarations relating to employment, consultancy, patents, products in development, or marketed products, etc.

Within your Competing Interests Statement, please confirm that this commercial affiliation does not alter your adherence to all PLOS ONE policies on sharing data and materials by including the following statement: \"This does not alter our adherence to PLOS ONE policies on sharing data and materials." (as detailed online in our guide for authors <http://journals.plos.org/plosone/s/competing-interests>). If this adherence statement is not accurate and there are restrictions on sharing of data and/or materials, please state these. Please note that we cannot proceed with consideration of your article until this information has been declared.

Please include both an updated Funding Statement and Competing Interests Statement in your cover letter. We will change the online submission form on your behalf.

Please know it is PLOS ONE policy for corresponding authors to declare, on behalf of all authors, all potential competing interests for the purposes of transparency. PLOS defines a competing interest as anything that interferes with, or could reasonably be perceived as interfering with, the full and objective presentation, peer review, editorial decision-making, or publication of research or non-research articles submitted to one of the journals. Competing interests can be financial or non-financial, professional, or personal. Competing interests can arise in relationship to an organization or another person. Please follow this link to our website for more details on competing interests: <http://journals.plos.org/plosone/s/competing-interests>

RESPONSE: AVD is an expert in the field of TB diagnosis and treatment. He worked for decades for Damien Foundation (DF) in their NGO medical aid projects, in one of which the study was conducted, and the Institute of Tropical Medicine Antwerp (ITM), where samples were send. Neither of those is of a commercial nature. Now he is retired. Given his expertise he still contributes to DF and ITM activities in general. Contribution to this specific study was not specified in the consultancy contract. He has no competing interests and no commercial affiliation. Therefore the statement "The authors received no specific funding for this work" applies to all authors.

Reviewers\' comments:

Reviewer\'s Responses to Questions

Comments to the Author

1\. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer \#1: Yes

\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

2\. Has the statistical analysis been performed appropriately and rigorously?

Reviewer \#1: Yes

\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

3\. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data---e.g. participant privacy or use of data from a third party---those must be specified.

Reviewer \#1: Yes

\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

4\. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer \#1: Yes

\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

5\. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer \#1: The authors demonstrate in scientifically sound and convincing way the important role played by 2nd line injectables in preventing recurrence with acquired resistance to Gatifloxacine, the core drug in the hitherto most effective shorter treatment regimen (STR) of rifampicin resistant tuberculosis (RR-TB). Subsequently, they plead for the necessity to include in the evaluation of all-oral RR-TB regimens - promoted since 2019 by WHO alternatively to STRs including injectables - an assessment of regimen compositions on resistance acquisition. The study is an important contribution to the ongoing discussion about merit and virtue of the standardized 'Bangladesh' STR and its variants using injectables for programmatic management of RR-TB in L/MICs where treatment options after recurrence are limited and will be so in a foreseeable future.

RESPONSE: Many thanks for your encouraging feedback

Minor suggestions

Title

Consider adding "...in RR-TB STR..."

RESPONSE: The revised title reads as follows: "Injectables' key role in rifampicin-resistant tuberculosis shorter treatment regimen outcomes"

Discussion

L289-90 Also understandable from the context, consider re-wording (...two days is not

appropriate for all TB drugs." -- "Two days of (what)...".

RESPONSE: The text was revised as follows: "Besides EBA estimates being prone to considerable variation, assessment at two days treatment is not appropriate for all TB drugs"

\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

6\. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer \#1: No

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, <https://pacev2.apexcovantage.com/>. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at <figures@plos.org>. Please note that Supporting Information files do not need this step.

###### 

Submitted filename: Response_to_reviewers_KM_2M.docx

###### 

Click here for additional data file.
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Dear Dr. Decroo,

We're pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you'll receive an e-mail detailing the required amendments. When these have been addressed, you'll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at <http://www.editorialmanager.com/pone/>, click the \'Update My Information\' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at <authorbilling@plos.org>.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they'll be preparing press materials, please inform our press team as soon as possible \-- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact <onepress@plos.org>.

Kind regards,

Olivier Neyrolles

Section Editor

PLOS ONE
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Injectables' key role in rifampicin-resistant tuberculosis shorter treatment regimen outcomes

Dear Dr. Decroo:

I\'m pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they\'ll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact <onepress@plos.org>.

If we can help with anything else, please email us at <plosone@plos.org>.

Thank you for submitting your work to PLOS ONE and supporting open access.

Kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr. Olivier Neyrolles

Section Editor

PLOS ONE
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